PT - JOURNAL ARTICLE AU - Webster, Anthony J. TI - Causal attribution fractions for epidemiological studies, applied to a UK Biobank study of smoking and BMI AID - 10.1101/2021.12.24.21268368 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.24.21268368 4099 - http://medrxiv.org/content/early/2021/12/25/2021.12.24.21268368.short 4100 - http://medrxiv.org/content/early/2021/12/25/2021.12.24.21268368.full AB - Epidemiological studies often use proportional hazard models to estimate associations between potential risk factors and disease risk. It is emphasised that when the “backdoor criteria” from causal-inference applies, if diseases are sufficiently rare, then the proportional hazard model can be used to estimate causal associations. When the “frontdoor criteria” applies (allowing causal estimates with unmeasured confounders), similar estimates are found to mediation analyses with measured confounders. Reasons for this are discussed. An attribution fraction is constructed using the average causal effects (ACE) of exposures on the population, and simple methods for its evaluation are suggested. It differs from the attribution fraction used by the World Health Organisation (WHO), except for specific circumstances where the latter can agree or provide a bound. A counterfactual argument determines an individual’s attribution fraction Af in terms of proportional hazard estimates, as Af = 1− 1/R, where R is an individual’s relative risk. Causally meaningful attribution fractions cannot be constructed for all known risk factors or confounders, but there are important cases where they can. As an example, systematic proportional hazards studies with UK Biobank data estimate the attribution fractions of smoking and BMI for 226 diseases. The attribution of risk is characterised in terms of disease chapters from the International Classification of Diseases (ICD-10), and the diseases most strongly attributed to smoking and BMI are identified. The result is a quantitative characterisation of the causal influence of smoking and BMI on the landscape of disease incidence in the UK Biobank population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by a fellowship from the Nuffield Department of Population Health, University of Oxford.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study uses UK Biobank data, that is available by application from: www.ukbiobank.ac.ukI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study uses UK Biobank data, that is available by application from: www.ukbiobank.ac.uk https://www.ukbiobank.ac.uk